Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 13;24(2):1604.
doi: 10.3390/ijms24021604.

Skin Cancer Metabolic Profile Assessed by Different Analytical Platforms

Affiliations
Review

Skin Cancer Metabolic Profile Assessed by Different Analytical Platforms

Yousra A Hagyousif et al. Int J Mol Sci. .

Abstract

Skin cancer, including malignant melanoma (MM) and keratinocyte carcinoma (KC), historically named non-melanoma skin cancers (NMSC), represents the most common type of cancer among the white skin population. Despite decades of clinical research, the incidence rate of melanoma is increasing globally. Therefore, a better understanding of disease pathogenesis and resistance mechanisms is considered vital to accomplish early diagnosis and satisfactory control. The "Omics" field has recently gained attention, as it can help in identifying and exploring metabolites and metabolic pathways that assist cancer cells in proliferation, which can be further utilized to improve the diagnosis and treatment of skin cancer. Although skin tissues contain diverse metabolic enzymes, it remains challenging to fully characterize these metabolites. Metabolomics is a powerful omics technique that allows us to measure and compare a vast array of metabolites in a biological sample. This technology enables us to study the dermal metabolic effects and get a clear explanation of the pathogenesis of skin diseases. The purpose of this literature review is to illustrate how metabolomics technology can be used to evaluate the metabolic profile of human skin cancer, using a variety of analytical platforms including gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and nuclear magnetic resonance (NMR). Data collection has not been based on any analytical method.

Keywords: analytical platforms; biomarkers; cancer; metabolic profile; metabolomic; omics; proteomic; skin cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest in relation to this study. This research is part of the -Human Disease Biomarkers Discovery Research Group-study.

Figures

Figure 2
Figure 2
Correlation between Skin and Blood Metabolites.
Figure 1
Figure 1
Metabolomic analysis advantages over other omics technologies.
Figure 3
Figure 3
Process of dermal metabolomics.

Similar articles

Cited by

References

    1. Morze J., Danielewicz A., Przybyłowicz K., Zeng H., Hoffmann G., Schwingshackl L. An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer. Eur. J. Nutr. 2021;60:1561–1586. doi: 10.1007/s00394-020-02346-6. - DOI - PMC - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Saba T. Computer vision for microscopic skin cancer diagnosis using handcrafted and non-handcrafted features. Microsc. Res. Tech. 2021;84:1272–1283. doi: 10.1002/jemt.23686. - DOI - PubMed
    1. Toğaçar M., Cömert Z., Ergen B. Intelligent skin cancer detection applying autoencoder, MobileNetV2 and spiking neural networks. Chaos Solitons Fractals. 2021;144:110714. doi: 10.1016/j.chaos.2021.110714. - DOI
    1. Haggenmüller S., Maron R.C., Hekler A., Utikal J.S., Barata C., Barnhill R.L., Beltraminelli H., Berking C., Betz-Stablein B., Blum A., et al. Skin cancer classification via convolutional neural networks: Systematic review of studies involving human experts. Eur. J. Cancer. 2021;156:202–216. doi: 10.1016/j.ejca.2021.06.049. - DOI - PubMed